SequelSEC

Akebia Therapeutics, Inc. AKBA

Pharmaceutical Preparations · CIK 0001517022 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$219.06M
Fiscal year ended 2026-06-30
Operating income
-$15.13M
Fiscal year ended 2026-06-30
Free cash flow
$40.26M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$946.38MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.53Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity29.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin28.7%93th
CapEx / revenue0.1%11th
Long-term debt / equity1.48x89th
Operating margin9.9%85th
SBC / revenue4.8%20th
Current ratio1.55x22th
Net margin-2.3%75th
Revenue YoY growth47.5%75th
R&D / revenue26.4%27th
Gross margin83.3%72th

Akebia Therapeutics, Inc. (AKBA) reported revenue of $219.06M and net income of -$29.67M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Akebia Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Akebia Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$219.06M
Cost of revenue$44.63M
Gross profit$174.43M
Operating income-$15.13M
Net income-$29.67M
Research & development$70.46M
Weighted-average diluted sharesUnavailable
Pretax income-$27.85M
Income tax expense$1.82M
Diluted EPSUnavailable
Selling, general & administrative$113.79M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Akebia Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$155.55M
Total assets$349.66M
Current assets$229.55M
Total liabilities$324.64M
Current liabilities$160.86M
Total equity incl. NCI$25.02M
Temporary (mezzanine) equityUnavailable
Inventory$13.02M
Accounts receivable$53.51M
Goodwill$59.04M
Long-term debt$24.75M
Accounts payable$9.42M

Cash flow

Akebia Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$41.55M
Capital expenditures$1.29M
Investing cash flow-$12.10M
Financing cash flow-$11.20M
Net change in cash$18.26M
Stock-based compensation$13.31M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Akebia Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$40.26M
Gross margin79.6%
Operating margin-6.9%
FCF margin18.4%
SBC / revenue6.1%
Current ratio1.43x
Revenue YoY growth7.5%
Net margin-13.5%
R&D / revenue32.2%
CapEx / revenue0.6%
Long-term debt / equity0.99x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AKBA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.